Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin in Mild to Moderate Ulcerative Colitis
NCT05058417Phase 2Withdrawn
- Sponsor
- Sadat City University
- Start
- Oct 2021
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of empagliflozin in ulcerative colitis (UC), sponsored by Sadat City University. Planned start Oct 2021; status: withdrawn.
02
Drugs
empagliflozin
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT05058417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05058417.